V599EB-RAF is an Oncogene in Melanocytes

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2338-2342

  Wellbrock, Claudia ^a   Ogilvie, Lesley ^a   Hedley, Douglas ^a   Karasarides, Maria ^a   Martin, Jan ^a   Niculescu Duvaz, Dan ^a   Springer, Caroline J ^a   Marais, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; B RAF KINASE; BRAF PROTEIN, MOUSE; CARCINOGEN; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B RAF GENE; B RAF V599E GENE; CANCER STAGING; CARCINOGENESIS; CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOCYTE; MOUSE; NEVUS; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL TRANSFORMATION; FEMALE; GENETIC TRANSFECTION; GENETICS; MELANOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOGENS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; ONCOGENES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION;

EID: 1942506706     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3433     Document Type: Article

References (21)

1. van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883-93.
2. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMACI alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800-4.
3. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-34.
4. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003;22:3063-9.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature (Lond) 2002;417:949-54.
6. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
7. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
8. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-5.
9. Bohm M, Moellmann G, Cheng E, et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995;6:291-302.
10. Imokawa G, Kobayasi T, Miyagishi M. Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes. Cross-talk via trans-activation of the tyrosine kinase c-kit receptor. J Biol Chem 2000;275:33321-8.
11. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002;277:6443-54.
12. Wilson RE, Dooley TP, Hart IR. Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancer Res 1989;49:711-6.
13. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 1992;7:2315-21.
14. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987;39:414-8.
15. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985;5:3610-6.
16. Leevers SJ, Marshall CJ. Activation of extracellular signal-regulated kinase, ERK2, by p21 ras oncoprotein. EMBO J 1992;11:569-74.
17. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (ed. 2). Br J Cancer 1998;77:1-10.
18. Englaro W, Bertolotto C, Busca R, et al. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem 1998;273:9966-70.
19. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
20. Sviderskaya EV, Hill SP, Evans-Whipp TJ, et al. p161nk4a in melanocytes and differentiation. J Natl Cancer Inst (Bethesda) 2002;94:446-54.
21. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.